Source: Health Canada shortage reports · Updated Aug 13, 2026
Some Teriparatide products are in shortage in Canada (1 of 4 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Oct 23, 2026.
A parathyroid hormone medicine used to treat osteoporosis at high risk of fracture.
Products affected
1 / 4
In shortage since
Aug 11, 2026
Est. full return
Oct 23, 2026
Reports on file
8
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
APO-TERIPARATIDE INJECTION
250MCG · SOLUTION · APOTEX INC
DIN 02498804 · since Aug 11, 2026, est. end Oct 23, 2026 · Disruption of the manufacture of the drug.
Discontinued
FORTEO
250MCG · SOLUTION · ELI LILLY CANADA INC
DIN 02254689
Resolved
TEVA-TERIPARATIDE INJECTION
250MCG · SOLUTION · TEVA CANADA LIMITED
DIN 02486423 · ended Feb 25, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-TERIPARATIDE INJECTION
250MCG · SOLUTION · APOTEX INC
DIN 02498804 · ended Feb 12, 2026 · Disruption of the manufacture of the drug.
Resolved
TEVA-TERIPARATIDE INJECTION
250MCG · SOLUTION · TEVA CANADA LIMITED
DIN 02486423 · ended Jul 15, 2025 · Disruption of the manufacture of the drug.
Resolved
APO-TERIPARATIDE INJECTION
250MCG · SOLUTION · APOTEX INC
DIN 02498804 · ended May 1, 2025 · Disruption of the manufacture of the drug.
Resolved
OSNUVO
250MCG · SOLUTION · AVIR PHARMA INC.
DIN 02495589 · ended Mar 17, 2023 · Delay in shipping of the drug.
Resolved
TEVA-TERIPARATIDE INJECTION
250MCG · SOLUTION · TEVA CANADA LIMITED
DIN 02486423 · ended Dec 14, 2022 · Disruption of the manufacture of the drug.
What's happening
Teriparatide is currently affected by an active shortage report filed with Health Canada by APOTEX INC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Teriparatide is classified under “PARATHYROID HORMONES AND ANALOGUES” (ATC H05AA).
Recent changes
Aug 13, 2026
New report filed
Common questions
What is Teriparatide used for?
A parathyroid hormone medicine used to treat osteoporosis at high risk of fracture.
When will Teriparatide be back in stock in Canada?
The latest manufacturer estimate is Oct 23, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Teriparatide in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.